Two radically new drugs give hope to people with depression. But psychiatrists are skeptical.


Both drugs have been criticized for their high cost and the fact that both are difficult to administer. Brexanolone costs an average of $ 34,000, plus the price of a multi-day hospital stay, although FDA approval means that insurance can cover at least one part of the costs. Meanwhile, to make a profit on ketamine, which cannot be patented, the research division of Johnson & Johnson, Janssen, has isolated S-ketamine, one of the two mirror image molecules. that make up the drug's original compound, and turned it into a nasal spray. . A dose of the resulting product, esketamine, costs up to $ 885, and this is in addition to the cost of administering a medical office – a requirement because the substance is always "classified".